See Spot Run Meningococcal update 2017
|
|
- Barry Austin
- 5 years ago
- Views:
Transcription
1 See Spot Run Meningococcal update 2017 Jim Buttery Infection and Immunity Monash Children s Hospital Monash Health Monash University SAEFVIC
2 How serious a disease is N meningitidis? Meningococcal disease has a case fatality rate of approximately 10%, however more deaths are caused by septicaemia than by meningitis
3 Nasophayngeal colonisation Scanning electron micrograph: attachment of N. meningitidis by pili to the microvilli of noncilited cells in the nasopharynx Colonisation Common transient Increased in adolescence Majority- totally asymptomatic
4 Invasive Meningococcal Disease Age specific notification rates of invasive meningococcal disease, Australia
5 Risk factors: meningococcal disease Immature Immune System 1 Impaired Immune System 2,3 Nasopharyngeal Irritation 3 Social Factors 3,4 Infants Asplenia Smoking Close contact - case Waning Ab PS response Complement deficiency Humoral deficiency Respiratory-tract infection Crowding Mult kissing contacts Prematurity HIV/AIDS Pubs/Discos Most cases of meningococcal disease occur in previously healthy persons without identified risk factors 1. Rosenstein NE,et al. N Eng J Med. 2001;344: ; 2. Figueroa JE, et al. Clin Microbiol Rev. 1991;4: ; 3. Bilukha OO, et al. MMWR Recomm Rep. 2005;54:1 21; 4. Imrey PB, et al. J Clin Microbiol. 1995;33:
6 Meningococcal Epidemiology Victoria
7 Meningococcal notifications Vic population Courtesy Lucinda Franklin/Kath Taylor, DHHS Victoria
8 Meningococcal immunity Goldschneider et al. J. Exp. Med. 129:1307, 1969
9 Invasive meningococcal disease Serogroup and Year Victoria: 2000 to 2017 (YTD) MenCCV 12mo dose (from Jan 2003) catch-up 1-19yo's ( ) Y W C B Number of notifications A Not further specified Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3 Q Year and quarter Courtesy Lucinda Franklin, DHHS Victoria
10 Invasive meningococcal disease Serogroup and Year Victoria: 2013 to 2017 (YTD) 90 Number of Notifications not further specified 2 Y 9 W C B (till 21 June) Year Courtesy Lucinda Franklin, DHHS Victoria 2 January 2018
11 Invasive meningococcal disease Serogroup and Age Victoria: 2013 to 2017 YTD 50 Number of Notifications Not further specified Y W C B Age (years) Courtesy Lucinda Franklin, DHHS Victoria 2 January 2018
12 Invasive meningococcal disease Age group by year Victoria: 2013 to 2017 YTD 90 Number of Notifications Age (years) Courtesy Lucinda Franklin, DHHS Victoria 2 January 2018
13 MenW Victoria: (YTD) Female to Male = 50:36 ICU = 44% 5 deaths ages 18, 19, 46, 69 and 73 yrs Courtesy Lucinda Franklin, DHHS Victoria 2 January 2018
14 Meningococcal vaccine history Aust 1970 s Polysaccharides developed incl ACWY 1991 MenACWY PS 1 st recommendation (Haj) st Men C conjugate licensed 2003 Funded MenC program (12m) 2010 Hib MenC registered st Men ACWY conjugate registered st Men B (4vMenB) registered 2017 Men ACWY conj jurisdictions funded yr one Men ACWY conjugate age lowered to 2m
15 Meningococcal ACWY Glycoconjugate Vaccines Menactra (MCV4-D) Licensed 2005 US: 2010 Australia Approved for use in those 9 months 55 years, IM A,C,Y,W-135 conjugated to diphtheria toxoid Does not require reconstitution Menveo (MCV4-CRM) Licensed 2011 Approved for use in those 2 months 55 years, IM A,C,Y,W-135 conjugated to CRM197 Requires reconstitution Nimenrix (MCV4-TT) Licensed 2013 Approved for use in those 6w months 55 years, IM A,C,Y,W-135 conjugated to CRM197 Requires reconstitution
16 Victoria Adolescent program: Meningococcal ACWY conjugate Began term All young people aged 15 to 19 years between 18 April 2017 and 31 December dose Menactra Secondary school program - Also available from GPs or local council community immunisation service
17 4CMenB GpB PS- polymer of sialic acid: chemically identical to polysaccharides found in human tissues during development (2 8)-α-Neu5Ac as a self antigen of humans potential cause of immunopathology
18 4CMenB: Bexsero Capsular PS: shared by all Proteins: more variable between strains of Group B Aust strains will share 0-4 of vaccine peptides
19 MATS: infant immuno & persistence Immunogenicity varies between proteins Immune response wanes: amount also varies
20 100 BEXSERO Tolerability in Infants Solicited systemic reactions when BEXSERO is given with routine vaccines post dose 1 BEXSERO+Routine MenC+Routine Routine Severe 80 % of infants Changed eating habits Sleepiness Vomiting Diarrhea Irritability Unusual crying Post dose 1 Rash Fever 38.5 C *No increase in the incidence or severity of the adverse reactions was seen with subsequent doses of the vaccination series. Routine vaccines: PCV7 and DTaP-HBV-IPV/Hib; BEXSERO+Routine: N=2478; MenC+Routine: N=490; Routine: N=659. Fever was categorized as severe if temperature was 40 C. All other reactions were categorized as severe if subject was unable to perform normal daily activities. 1. Vesikari T, et al. Lancet. 2013;381: ; 2. Data on file, Novartis Vaccines and Diagnostics; 3. TGA Approved Product Information, 14 August 2013
21 When Fever Occurred, it Generally Followed a Predictable Pattern, With the Majority Resolving the Day After Vaccination BEXSERO given with routine vaccines post dose Post dose 1 (2-4-6 month dosing schedule) BEXSERO+Routine* MenC+Routine* Routine* 40 C % of infants C <40.0 C 38.5 C <39 C hrs 24 hrs 48 hrs 72 hrs Time Inform your patients about the likelihood of fever lasting one to two days *Routine vaccines: PCV7 and DTaP-HBV-IPV/Hib; BEXSERO+Routine: N= ; MenC+Routine: N= ; Routine only: N= Fever was defined as rectal temperature 38.5 C. 1. Vesikari T, et al. Lancet. 2013;381: ; 2. Data on file, Novartis Vaccines and Diagnostics; 3. TGA Approved Product Information, 14 August 2013
22 Prophylactic Paracetamol at the Time of and Closely After Vaccination Reduced Fever When BEXSERO is given concomitantly with routine infant vaccines % of subjects Post dose 1 (of month dosing schedule) NPP PP NPP PP NPP PP 6 hrs 48 hrs 72 hrs Time 40 C 39 C <40.0 C 38.5 C <39 C Prophylactic Paracetamol Did Not Impact Immunogenicity of Routine Vaccines Advise your patients that the prophylactic administration of paracetamol at the time and closely after vaccination can reduce the incidence and intensity of post-vaccination febrile reactions NPP: no prophylactic paracetamol (N=182); PP: with prophylactic paracetamol (N= ). Routine vaccines: PCV7 and DTaP-HBV-IPV/Hib. 1. Prymula R, et al. Presented at: 29th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID); June 7-10, 2011; The Hague, The Netherlands. Poster #631; 2. Data on file, Novartis Vaccines and Diagnostics; 3. TGA Approved Product Information, 14 August 2013
23 Predicted Coverage of MenB Strains Indicates BEXSERO Has the Potential to Impact MenB Disease 66% 91% 85% 85% 73% 73% 82% 82% 74% 85% 85% 87% 87% 69% 88% 81% 76% Canada: Bettinger J, et al. Presented at: 5th Vaccine & ISV Annual Global Congress; October 2-4, 2011; Seattle, WA; US: Kim E, et al. Presented at: 19th IPNC. September 9-14, Würzburg, Germany. Poster P270; Brazil: Lemos AP, et al. Presented at: 19th IPNC. September 9-14, Würzburg, Germany. Poster P272; Europe: Vogel U, et al. Lancet Infect Dis. 2013;13: ; Greece: Data on file, Novartis Vaccines and Diagnostics; Australia: Nissen M, et al. Presented at: 19th IPNC. September 9-14, Würzburg, Germany. Poster P269.
24 In March 2014, the Department of Health s Technical Advisory Group on Immunisation issued Advice for immunisation providers regarding the use of Bexsero
25 Recommendations Based on their higher disease risk, 4CMenB is recommended for: Infants and young children, particularly those aged <24 months Adolescents aged 15 to 19 years Children and adults with medical conditions that place them at a high risk of IMD, such as functional or anatomical asplenia or complement component disorders (see Chapter 4.10 of The Australian Immunisation Handbook, 10th edition1) Laboratory personnel who frequently handle Neisseria meningitidis. 4CMenB is also recommended for all children and young adults who wish to reduce their risk of MenB IMD.
26 DOH Australian Technical Advisory Group on Immunisation (ATAGI) Advice Table 1. Recommended schedule of 4CMenB by age group Age at commencement of vaccine course Primary immunisation Interval between primary doses Age for booster dose 2 months* 3 doses, delivered at ~2*, 4 and 6 months of age; (intervals ~2 months, at least 1 month) 12 months 3 to 5 months 3 doses 1 2 months 12 months 6 to 11 months 2 doses 2 months 12 months, or 2 months after previous dose, whichever is later 12 months to 10 years 2 doses 2 months No booster required 11 years and above 2 doses 1 2 months No booster required * 4CMenB is registered for use in persons 2 months of age; however, the 1st dose of 4CMenB may be administered as early as 6 weeks of age to align with the NIP infant schedule. The need for a booster dose for this age group is as yet uncertain. There are currently no data on the use of 4CMenB in individuals aged over 50 years, however, based on first principles, ATAGI recommends that 4CMenB can be used in older persons who are at high risk of IMD.
27 Known unknowns Will it work? Modified serology says yes Early data encouraging Will it provide herd immunity? reduction in NP carriage 12.6% ( 15.9%, 34.1%) Will protection last? Will there be escape strains? Will it increase fever/ febrile convulsions? Early data encouraging Will Australians follow paracetamol advice? Will that change febrile seizure risk anyway? How will we register adolescent doses?
28 Two-dose vaccine effectiveness was 82 9% (95% CI ) against all MenB cases
29 Safety (UK) Routine 3 doses paracetamol (?compliance) No increase in Febrile Seizure presentations HPA Increase in 2 and 4 m infants febrile presentations to ED Septic work ups Nainani, Archives Dis Child 2017 No increase ED presentations at 12m Neda So, 2017 (in press)
30 Life is like a box of chocolates
31 Conclusions Men W increasing esp adults Jurisdictional based programs ACWY Year 10 MenB Failed x 3 PBAC waiting on UK data More reactogenic but appears to be effective and safe (used with paracetamol)
32 Thank you
Invasive Meningococcal Disease - prevention through vaccination
Invasive Meningococcal Disease - prevention through vaccination Dr Shamez Ladhani Paediatric Infectious Diseases Consultant Public Health England Email: shamez.ladhani@phe.gov.uk a pain you cannot describe
More informationMENINGITIS WHAT S NEW? 3 RD NOVEMBER 2018
MENINGITIS WHAT S NEW? 3 RD NOVEMBER 2018 CONFLICTS OF INTEREST Educational travel grant - Gilead JIM NEWCOMBE FRCPA FRACP ID PHYSICIAN, ROYAL NORTH SHORE HOSPITAL, SYDNEY CLINICAL MICROBIOLOGIST, DOUGLASS
More informationQ21. Where can I find more information on meningococcal disease and vaccines?
FREQUENTLY ASKED QUESTIONS This fact sheet provides responses to some common questions about meningococcal vaccines, focusing on quadrivalent meningococcal conjugate vaccines (4vMenCVs). More detailed
More informationMeningococci and meningococcal disease
Australian Technical Advisory Group on Immunisation (ATAGI) Statement Advice for immunisation providers regarding the use of Bexsero a recombinant multicomponent meningococcal B vaccine (4CMenB) March
More informationInvasive Meningococcal Disease - prevention through vaccination
Invasive Meningococcal Disease - prevention through vaccination Dr Shamez Ladhani Paediatric Infectious Diseases Consultant Public Health England Email: shamez.ladhani@phe.gov.uk a pain you cannot describe
More informationMulticomponent MenB Vaccine (4CMenB): An Innovative Step In the Global Fight Against Serogroup B Meningococcal Disease
Multicomponent MenB Vaccine (4CMenB): An Innovative Step In the Global Fight Against Serogroup B Meningococcal Disease Jeffrey J. Stoddard, MD, FAAP Head, Global Medical Affairs Novartis Vaccines and Diagnostics
More informationBACTERIAL MENINGITIS IN CHILDREN
Overview Bacterial meningitis in children : rare, severe, mostly preventable What should GPs advise Australian parents in 2018? Peter McIntyre Professorial Fellow, National Centre for Immunisation Research
More informationPrevention of Meningococcal Disease. Marco Aurélio P. Sáfadi, MD, PhD FCM da Santa Casa de São Paulo
Prevention of Meningococcal Disease Marco Aurélio P. Sáfadi, MD, PhD FCM da Santa Casa de São Paulo Outline of the presentation Brief overview on the burden of MD Lessons learned with plain polysaccharide
More informationChanges to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25
Changes to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25 An update for registered healthcare practitioners August 2014 Quality Education
More informationMeningococcal vaccines and Herd protection. Potential Role, Coverage and Impact on carriage of the New Serogroup B protein vaccines in the Region
Meningococcal vaccines and Herd protection. Potential Role, Coverage and Impact on carriage of the New Serogroup B protein vaccines in the Region Ricardo Rüttimann Pediatric Infectious Diseases FUNCEI
More informationIntroduction of a meningococcal ACWY immunisation programme for adolescents
Introduction of a meningococcal ACWY immunisation programme for adolescents Information for registered healthcare practitioners Acknowledgement: This resource has been adapted with the permission of Public
More informationWhose Calling the Shots? - A 2019 Vaccine Update. Frank Bell Swedish Pediatric Infectious Disease Jan 2019
Whose Calling the Shots? - A 2019 Vaccine Update Frank Bell Swedish Pediatric Infectious Disease Jan 2019 2019 Vaccine Update Vaccines Meningococcal serogroup B HPV Pertussis Influenza Children with uncertain
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationAdult Pneumococcal Disease
Adult Pneumococcal Disease Reviewed and updated July 2018 S. pneumoniae and pneumococcal disease The bacterium Streptococcus pneumoniae causes pneumococcal disease S. pneumoniae is commonly found in human
More information9/12/2018. Meningococcal Disease and Meningococcal Vaccine. Neisseria meningitidis. Meningococcal Disease Pathogenesis. Aerobic gram-negative bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Meningococcal Disease and Meningococcal Vaccine Adult Track Chapter 14 Photographs and images included
More informationBackground Rationale of resource Please note:
Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) convened a meningococcal subcommittee to conduct a comprehensive and detailed assessment of the evidence on the meningococcal
More informationExperience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada
Experience with Quadrivalent Meningococcal Conjugate Vaccines (MenACWY) in Adolescent Vaccine Programs in the United States and Canada Jessica MacNeil, MPH Epidemiologist Centers for Disease Control and
More informationCONJUGATE MENINGOCOCCAL (ACWY) VACCINE
Cumbria & Lancashire Vaccine PGD Group ADVISORY INFORMATION FOR USE WITH PATIENT SPECIFIC DIRECTION OR INDIVIDUAL PRESCRIPTION SIGNED BY GP OR NON-MEDICAL PRESCRIBER. CONJUGATE MENINGOCOCCAL (ACWY) VACCINE
More informationMeningococcal disease and vaccination in the UK
Meningococcal disease and vaccination in the UK Ray Borrow Professor of Vaccine Preventable Diseases, Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester, U.K. ray.borrow@hpa.org.uk
More informationDisclosure Statement. Encapsulated Bacteria. Functions of the Spleen 10/25/2017. Pharmacist Learning Objectives
Pharmacist Learning Objectives No Spleen? No Problem. A Review of Vaccinations Indicated for the Asplenic Patient SCSHP Fall Meeting October 26, 2017 Explain the rationale for vaccinations in Select the
More informationBackground In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) convened a meningococcal subcommittee to conduct a comprehensive and
Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) convened a meningococcal subcommittee to conduct a comprehensive and detailed assessment of the evidence on the meningococcal
More informationMaternal immunisation and infant immunisation: core business for GPs What s new in 2017?
Maternal immunisation and infant immunisation: core business for GPs What s new in 2017? Peter McIntyre Director, National Centre for Immunisation Research & Surveillance Senior Staff Specialist, Children
More informationMeningococcal vaccines
Meningococcal vaccines Rodolfo Villena, MD Pediatric Infectious Diseases Hospital de niños Dr. Exequiel González Cortés Universidad de Chile Clínica Las Condes Disclosures Speaker at sponsored training
More informationOutsourcing in Clinical Trials 1-2 July 2015
Outsourcing in Clinical Trials 1-2 July 2015 Innovating Dr Chris Bailey Babraham Research Campus Babraham Cambridge CB22 3AT UK +44 (0)1223 496115 Vaccines www.immbio.com 1 Utilising Academia for the Benefit
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No. 31 Meningococcal group B (MenB) programme Classification: official NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationPediatric and Adolescent Vaccines
Pediatric and Adolescent Vaccines Andrea A. Berry, M.D. Division of Infectious Diseases and Tropical Pediatrics Center for Vaccine Development & Division of Malaria Research Overview Pediatric vaccine
More informationVaccines. Robert Read University of Southampton University Hospital Southampton
Vaccines Robert Read University of Southampton University Hospital Southampton Disclosures Non personal, non specific; Novartis-GSK Member, JCVI Editor in Chief, Journal of Infection, and Current Opinion
More informationA Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
Drugs (2014) 74:15 30 DOI 10.1007/s40265-013-0155-7 REVIEW ARTICLE A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program Miguel O Ryan Jeffrey Stoddard Daniela
More informationHemagglutinin Neuraminidase
Evolving Vaccine Guidance: Influenza, Meningococcal & HPV Vaccines H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Maine Chapter AAP Bar Harbor, Maine October 16, 2016
More informationPHAA Immunisaton Conference. Adelaide 5-7 June 2018
PHAA Immunisaton Conference Adelaide 5-7 June 2018 Good Public Health Messaging Reporting back Cold Chain Nurse Practitioner Immunisation Cold Chain Use of and access to thermostability data has been
More informationPRODUCT MONOGRAPH BEXSERO. Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection
PRODUCT MONOGRAPH BEXSERO Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection Active Immunizing Agent for the Prevention of Meningococcal Disease ATC Code: J07AH09
More informationCVU: What s new? 2 nd December 2013
CVU: What s new? 2 nd December 2013 Dr Margie Danchin Paediatrician, Department of General Medicine, RCH Senior Research Fellow, MCRI Senior Fellow, Department of Paediatrics, The University of Melbourne
More informationNHS public health functions agreement Service specification No. 31 Meningococcal group B (MenB) programme
NHS public health functions agreement 2017-18 Service specification No. 31 Meningococcal group B (MenB) programme Classification: official NHS public health functions agreement 2017-18 Service specification
More informationIn February 2015, the Joint Committee on Vaccination and Immunisation (JCVI) *
Background In 2015, Public Health England (PHE) reported a continued increase in meningococcal serogroup W cases in England. The rise was initially recorded in 2009 and since this time, cases have steadily
More informationInvasive Meningococcal Disease - prevention through vaccination
Invasive Meningococcal Disease - prevention through vaccination Dr Shamez Ladhani Paediatric Infectious Diseases Consultant Public Health England Email: shamez.ladhani@phe.gov.uk Vaccines against MenB
More informationPRODUCT MONOGRAPH NIMENRIX. Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine. Powder and diluent for solution for injection
PRODUCT MONOGRAPH Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine Powder and diluent for solution for injection Active Immunizing Agent Pfizer Canada Inc. 17,300 Trans-Canada Highway
More informationThe routine infant meningococcal B (MenB) vaccine against meningitis and septicaemia
The routine infant meningococcal B (MenB) vaccine against meningitis and septicaemia In the UK and Ireland babies are offered the MenB (meningococcal group B) vaccine, Bexsero, as part of the routine immunisation
More informationNHS public health functions agreement Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme
NHS public health functions agreement 2018-19 Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme 1 NHS public health functions agreement 2018-19 Service specification
More informationACIP Recommendation Update. Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego
ACIP Recommendation Update Mark H. Sawyer, MD UCSD School of Medicine Rady Children s Hospital San Diego What has ACIP been up to lately? New Recommendations Tdap vaccination for each pregnancy Meningococcal
More informationMENVEO powder and solvent for solution for injection Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine
1 NAME OF THE MEDICINE powder and solvent for solution for injection Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine Pharmacotherapeutic group: Meningococcal vaccines,
More informationPRODUCT MONOGRAPH BEXSERO. Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection
PRODUCT MONOGRAPH BEXSERO Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection Active Immunizing Agent for the Prevention of Meningococcal Disease ATC Code: J07AH09
More informationThe National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.
The National Immunisation Schedule Update and Current issues Dr Brenda Corcoran National Immunisation Office Objectives To outline immunisation schedules in Ireland Primary childhood schedule Vaccine uptake
More informationS404- Meningococcal Vaccines: Updated Policy Statement 2014
S404- Meningococcal Vaccines: Updated Policy Statement 2014 Michael T. Brady, MD Associate Medical Director Nationwide Children s Hospital Columbus, Ohio Disclosure of Relevant Relationship Dr. Brady (or
More informationPHN - Western Victoria Immunisation Forum Stephen Pellissier Manager Immunisation, DHHS 29 July 2017
PHN - Western Victoria Immunisation Forum 2017 Stephen Pellissier Manager Immunisation, DHHS 29 July 2017 Herding Cats 2016-17 Again a huge increase in political and media focus on immunisation and vaccination
More informationAndrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010
2010 Immunization Update Andrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010 Disclosures No financial conflict
More informationImmunization Update & focus on meningococcal vaccine PART 2
Immunization Update & focus on meningococcal vaccine PART 2 Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases University of Cape Town www.vacfa.uct.ac.za Meningococcal Disease
More informationPneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections
Pneumococcal vaccination in UK: an update Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections Leading infectious causes of mortality, 2000 WHO estimates 3.5 Deaths
More informationImmunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012
Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants
More informationPHN - Western Victoria Immunisation Forum Chelsea Taylor Senior Policy Advisor Immunisation, DHHS 21 October 2017
PHN - Western Victoria Immunisation Forum 2017 Chelsea Taylor Senior Policy Advisor Immunisation, DHHS 21 October 2017 Australian Immunisation Register (AIR) quarterly immunisation coverage data Victoria,
More informationImmunisation Update for Occupational Health
Immunisation Update for Occupational Health Dr Gayatri Amirthalingam Immunisation, Hepatitis & Blood Safety department Public Health England 29 th April 2016 Session Outline Epidemiology of vaccine preventable
More informationHyporesponsiveness: Time To Stop Using Meningococcal Polysaccharide Vaccines?
Hyporesponsiveness: Time To Stop Using Meningococcal Polysaccharide Vaccines? Lee H. Harrison, M.D. Professor of Medicine and Epidemiology University of Pittsburgh First Regional Meningococcal Symposium
More informationESCMID Online Lecture Library
What would be the best schedule for prevention of meningococcal disease in all ages? Ray Borrow ray.borrow@phe.gov.uk Public Health England, Manchester, UK MCC vaccine programme - UK In November 1999,
More informationMeningococcal Disease in Travellers
Meningococcal Disease in Travellers Please find product Prescribing Information at the end of this presentation Meningococcal disease A rare but potentially serious illness in travellers1 Caused by the
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on CPS Meningococcal Vaccination These podcasts are designed to give medical students an overview of key topics in pediatrics.
More informationImmunisation against meningococcal B disease for infants aged from two months. Information for registered health care practitioners
Draft 6thJuly Immunisation against meningococcal B disease for infants aged from two months Information for registered health care practitioners Disclaimer These draft training resources have been prepared
More information31/10/2017 COI. Travel Vaccination Update. Outline. General Advice. Steffen graph: travel epi. Checklist. Current nil
Travel Vaccination Update COI Current nil Nigel Crawford HealthEd, Brisbane October 2017 Historical pharmaceutical industry funding to my research institute (MCRI) for special risk and vaccine safety projects
More informationImmunization Guidelines for the Use of State Supplied Vaccine May 17, 2015
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationMeningococcal Disease and College Students
MASSACHUSETTS PUBLIC HEALTH FACT SHEET Meningococcal Disease and College Students May 2018 Page 1 of 4 What is meningococcal disease? Meningococcal disease is caused by infection with bacteria called Neisseria
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 October 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 October 2009 MENINGITEC suspension for injection in prefilled syringes meningococcal group C oligosaccharide conjugate
More informationChanges to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25 An update for registered
Changes to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25 An update for registered healthcare practitioners Frequently asked questions August
More informationA Licensed Combined Haemophilus influenzae Type b- Serogroups C and Y Meningococcal Conjugate Vaccine
Infect Dis Ther (2013) 2:1 13 DOI 10.1007/s40121-013-0007-5 REVIEW A Licensed Combined Haemophilus influenzae Type b- Serogroups C and Y Meningococcal Conjugate Vaccine Kirsten P. Perrett Terry M. Nolan
More information4/7/2017. Audrey Ofir, MD, MBA, FAAP University of Miami Miller School of Medicine Holtz Children Hospital
Audrey Ofir, MD, MBA, FAAP University of Miami Miller School of Medicine Holtz Children Hospital 1 9vHPV Tdap MCV LAIV HepB Children with Medical conditions 2 9vHPV vaccine HPV infection: Causes cervical,
More informationWHAT S NEW WITH VACCINATIONS IN 2016?
WHAT S NEW WITH VACCINATIONS IN 2016? MenB and a Few Other Changes Lynn Bahta, RN, PHN Immunization Clinical Consultant Minnesota Department of Health May 2016 Disclosure No conflict of interest Will discuss
More informationNational Immunisation Programme changes Michael Baker. Wessex Public Health England Centre
National Immunisation Programme changes 2013-14 Michael Baker Wessex Public Health England Centre Changes to the Meningococcal serogroup C conjugate (MenC) vaccine schedule in 2013 2 Immunisation Programme
More informationMeningococcal Education Program for Quebec Physicians: How Results Have Changed 2 Years after the Initial Program
Meningococcal Education Program for Quebec Physicians: How Results Have Changed 2 Years after the Initial Program Marc H. Lebel, MD, FRCPC John Yaremko, MD, FRCPC Anne Dionne, MD, FRCPC Anne-Julie Gaudreau,
More informationTo demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInvasive meningococal diseasefocus on Meningococcal B - epidemiology, international and Ireland
Invasive meningococal diseasefocus on Meningococcal B - epidemiology, international and Ireland Dr Suzanne Cotter, Health Protection Surveillance Centre (HPSC) Scope presentation Meningococccal disease
More informationAn Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)
+ An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Advice for the use of the Multicomponent Meningococcal Serogroup B (4CMenB) Vaccine TO PROMOTE AND PROTECT THE
More informationAustralian Technical Advisory Group on Immunisation Then and Now. Professor Terry Nolan AO
Australian Technical Advisory Group on Immunisation Then and Now Professor Terry Nolan AO Declarations See World Health Organisation SAGE website http://www.who.int/immunization/sage/meetings/2017/october/sa
More informationStudy No.: Title: Rationale: Phase: Study Periods: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationKeeping up with the immunization schedule: Meningococcal and More
Keeping up with the immunization schedule: Meningococcal and More DatTran, MD, MSc, FRCPC, FAAP Division of Infectious Diseases, The Hospital for Sick Children Department of Paediatrics, University of
More information12 Meningococcal disease
12 Meningococcal disease Key information Mode of transmission By respiratory droplets or direct contact with nasopharyngeal secretions from a carrier or case. Incubation period Period of communicability
More information2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS
IMMUNIZATION UPDATE 2015 Kelly Ridgway, RPh February 21, 2015 Today s Overview 1 2 3 4 5 6 Pneumococcal Vaccine Recommendations Meningococcal Vaccine Recommendations HPV Vaccine Recommendations Patient
More informationVaccination Update. Pregnancy. 24-May-17. Disclosures. Overview. Paul Van Buynder Professor, Griffith University Chairman, Immunisation Coalition
Vaccination Update Paul Van Buynder Professor, Griffith University Chairman, Immunisation Coalition Disclosures I have been involved in vaccine studies funded by CSL, Sanofi Pasteur, Merck and Novartis
More informationChanges to the Meningococcal C conjugate (MenC) vaccine schedule. Questions and Answers
Changes to the Meningococcal C conjugate (MenC) vaccine schedule Questions and Answers Background The meningococcal C (MenC) vaccination programme was first introduced into the UK routine immunisation
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAdult Pneumococcal Disease
Adult Pneumococcal Disease S. pneumoniae and pneumococcal disease The bacterium Streptococcus pneumoniae causes pneumococcal disease S. pneumoniae is commonly found in human nasopharynx (nose and throat)
More information1.3 Meningococcal Disease (Neisseria meningitidis) (invasive)
1.3 Meningococcal Disease (Neisseria meningitidis) (invasive) Summary Number of cases, 214: 82 Number of cases, 213: 81 Number of cases, 212: 66 Crude incidence rate, 214:1.8/1, Between and 212, a marked
More informationReview Article Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience
SAGE-Hindawi Access to Research Advances in Preventive Medicine Volume 2011, Article ID 846756, 17 pages doi:10.4061/2011/846756 Review Article Conjugate Meningococcal Vaccines Development: GSK Biologicals
More information2017 Vaccination Update
2017 Vaccination Update NATHAN BOONSTRA, MD General Pediatrician, Blank Pediatric Clinic TODAY S OBJECTIVES Review the latest recommendations for immunizations, including HPV Meningococcal vaccines Influenza
More informationMeningococcal Conjugate (Groups A, C, Y and W-135) Vaccine Biological Page
Meningococcal Conjugate (Groups A, C, Y and W-135) Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.281 Created by: Approved by: Province-wide Immunization Program Standards
More informationPreteen and teen vaccines: what to do with the recent recommendations
Preteen and teen vaccines: what to do with the recent recommendations MARK H. SAWYER UCSD SCHOOL OF MEDICINE RADY CHILDREN S HOSPITAL SAN DIEGO Continuing Education The Illinois Chapter, American Academy
More informationAdult Pneumococcal Disease
Adult Pneumococcal Disease S. pneumoniae and pneumococcal disease The bacterium Streptococcus pneumoniae causes pneumococcal disease S. pneumoniae is commonly found in human nasopharynx (nose and throat)
More informationPRODUCT MONOGRAPH NIMENRIX. Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine. Powder and diluent for solution for injection
PRODUCT MONOGRAPH NIMENRIX Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine Powder and diluent for solution for injection Active Immunizing Agent Pfizer Canada Inc. 17,300 Trans-Canada
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBCHOOSE TO VACCINATED. Ask your doctor about the MenB * vaccine.
BCHOOSE TO VACCINATED Vaccinate against meningococcal disease caused by Neisseria meningitidis group B strains (MenB) with BEXSERO BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed)
More informationThese immunisations will be offered on Tuesday 9 February by the School Nursing Team.
66 High Street Aylesbury HP20 1SD November 2015 www.buckshealthcare.nhs.uk Dear Stowe Parents and Guardians of Year 11 pupils Meningococcal ACWY Year 11 Pupils Meningococcal disease is a rare but life-threatening
More informationStudy No.: Title: Rationale: Note: Phase: Study Period: Study Design: Centres: Indication: Treatment: Hib-MenCY F1 Group Hib-MenCY F2 Group
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMenC. MenW MenY
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
AEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationMeningococcal Update. Disclosure. Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting
1 Meningococal and Influenza Vaccines Update! Robert Wittler, MD Sept 12, 2014 KAAP Fall CME Meeting 2 Disclosure Speakers Bureau: Sanofi Pasteur Vaccines and Novartis! I do not intend to discuss an unapproved/
More informationfor the New Zealand National Immunisation Schedule: Pneumococcal Auckland UniServices Limited A wholly owned company of The University of Auckland
2012 Antigen Review for the New Zealand National Immunisation Schedule: Pneumococcal Auckland UniServices Limited A wholly owned company of The University of Auckland Prepared for: New Zealand Ministry
More informationImmunization Update. William Atkinson, MD, MPH. Immunization Action Coalition
Immunization Update William Atkinson, MD, MPH Immunization Action Coalition Coordinated School Health Conference Lake Ozark, Missouri December 3, 2016 1 Disclosures William Atkinson has no financial relationships
More informationACIP Meeting Update, New Recommendations and Pending Influenza Season
ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting
More informationMeningococcal vaccine evolution*
J prev med hyg 2012; 53: 131-135 through childhood to a peak in 19-year-olds, who have a carriage rate of 20%, and declines in adulthood [7, 8]. Based on the chemical composition of the polysaccharide
More informationImmunisation against meningococcal B for infants aged from two months. Immunisation against meningococcal B disease for infants aged from two months
Immunisation against meningococcal B disease for infants aged from two months 1 Acknowledgement: This resource has been adapted with permission from Public Health England and Health Protection Scotland.
More informationAre you aged years old?
Are you aged 14 18 years old? Protect yourself against meningitis and septicaemia If you are aged 14 18 years old (or aged up to 25 years and starting university for the first time this year) you need
More informationHelp protect your baby against MenB
Help protect your baby against MenB 2015 New vaccine for babies available from 1 September 2015 1 From 1 September 2015, all babies born on or after 1 July 2015 will be offered the MenB vaccine along with
More informationPlatforms. Adolescent Immunization Update and the 16 Year Old Platform. Advisory Committee on Immunization Practices (ACIP)
Adolescent Immunization Update and the 16 Year Old Platform William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition Advisory Committee on Immunization Practices
More information